Table 2

Results of the univariate and multivariate analyses for factors associated with time to progression

Univariate HR95% CIp ValueMultivariate HR (n=72)95% CIp ValueBootstrapping (95% CI and p value)*
Visceral fat area
 <117.5811
 ≥117.582.231.353.700.0022.801.355.790.005(0.90 to 8.70) 0.075
Subcutaneous fat area
 <193.9211
 ≥193.921.620.982.690.0591.190.572.490.644(0.43 to 3.26) 0.735
WHO PS
 011
 11.831.013.320.0472.190.955.040.065(0.80 to 6.00) 0.126
 24.292.058.970.0015.492.0714.500.001(1.75 to 17.22) 0.004
BMI, kg/m2
 <23.611
 ≥23.61.123.060.0161.390.682.850.374(0.47 to 4.12) 0.557
Chemotherapy‡
 LV5FU11
 FOLFIRI0.460.161.320.1480.700.172.820.611(NC) 0.976
 FOLFOX0.520.181.520.2311.190.294.860.807(NC) 0.988
Liver metastases only
 No11
 Yes1.090.631.930.7432.120.934.830.073(0.48 to 9.36) 0.321
Age, years†1.010.991.040.3961.000.971.030.817(0.95 to 1.04) 0.882
Sex
 Male11
 Female0.820.501.360.4480.830.411.670.605(0.35 to 1.96) 0.675
CEA†1.000071.000021.00010.0031.000061.0000021.00010.04(0.99 to 1.00) 0.938
Kras status
 Wild type1
 Mutated1.150.562.370.701
Harrell's C-statistic0.78
AIC367
  • Owing to the number of patients with progression (n=64), the multivariate analysis was limited to nine variables.

  • * Two hundred replications.

  • hazard ratio for continuous variable was calculated for one unit.

  • FOLFIRI, LV5FU2 regimen plus irinotecan 180 mg/m2 every 2 weeks; FOLFOX, LV5FU2 regimen plus oxaliplatin 85 mg/m2; LV5FU, leucovorin 400 mg/m2 followed by 5-fluorouracil as a 400 mg/m2 bolus then a 2400 mg/m2 infusion over 46h.

  • AIC, Akaike information criterion; BMI, body mass index; CEA, carcinoembryonic antigen level in serum; WHO PS, performance status according to the World Health Organization.